Currently, numerous HDAC inhibitors, including trichostatin A, valproic acid, and Largazole, have been identified as potent inhibitors of HSC activation both in vitro and in vivo that could reduce inflammatory activity and liver fibrosis [31–33]. Here, HDAC9 is linked to Hepatic fibrosis.